OneWorld Health has received significant funding for this project from the Department for International Development (DfID) in the United Kingdom.
Anacor Pharmaceuticals CEO David Perry said the company has demonstrated that its boron-based chemistry platform and strength in antibacterial research has the potential to create new antibiotics.
"We hope to leverage these to address a disease that affects over one hundred million people annually," Perry said.